moomoo ID:NaN
Log Out
Log in to access Online Inquiry

Zylox-Tonbridge Medical Widens Loss as Expenses Surge in 2021

MT Newswires ·  {{timeTz}}

11:16 PM EDT, 03/15/2022 (MT Newswires) -- Zylox-Tonbridge Medical Technology (HKG:2190) widened its loss to 0.68 yuan ($0.11) per diluted share in 2021 from 0.52 yuan a year prior.

Loss attributable to equity holders of the company for the reported period expanded to 199.7 million yuan year over year from 100.5 million yuan, driven by a surge in administrative and selling and distribution expenses, according to a late Tuesday filing.

Revenue soared to 177.9 million yuan year over year from 27.6 million, buoyed by a 441.5% increase in sales turnover from certain products, such as Thrombite clot retriever device and intracranial support catheter.

Administrative expenses leapt 224.6% year over year to 100.6 million yuan, while selling and distribution expenses climbed 365.8% to 95.3 million yuan.

Shares of the medical device maker rose over 1% recently.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.